221 related articles for article (PubMed ID: 35890400)
1. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery.
Furman O; Zaporozhets A; Tobi D; Bazylevich A; Firer MA; Patsenker L; Gellerman G; Lubin BCR
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890400
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides.
Mansour S; Adhya I; Lebleu C; Dumpati R; Rehan A; Chall S; Dai J; Errasti G; Delacroix T; Chakrabarti R
Sci Rep; 2022 Dec; 12(1):20725. PubMed ID: 36456600
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
4. A novel cyclic NP1 reveals obstruction of EGFR kinase activity and attenuation of EGFR-driven cell lines.
Jiwacharoenchai N; Tabtimmai L; Kiriwan D; Suwattanasophon C; Seetaha S; Sinthuvanich C; Choowongkomon K
J Cell Biochem; 2022 Feb; 123(2):248-258. PubMed ID: 34633106
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.
Li Z; Zhao R; Wu X; Sun Y; Yao M; Li J; Xu Y; Gu J
FASEB J; 2005 Dec; 19(14):1978-85. PubMed ID: 16319141
[TBL] [Abstract][Full Text] [Related]
6. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
[TBL] [Abstract][Full Text] [Related]
7. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
8. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer.
Xiao W; Ma W; Wei S; Li Q; Liu R; Carney RP; Yang K; Lee J; Nyugen A; Yoneda KY; Lam KS; Li T
J Hematol Oncol; 2019 Jun; 12(1):56. PubMed ID: 31182116
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
10. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
